# Phase III Study to Evaluate the Efficacy and Safety of AD-209

> **NCT06348576** · PHASE3 · RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 280 (estimated)

## Conditions studied

- Hypertension,Essential

## Interventions

- **DRUG:** AD-209
- **DRUG:** AD-2091
- **DRUG:** AD-209 Placebo
- **DRUG:** AD-2091 Placebo

## Key facts

- **NCT ID:** NCT06348576
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2025-02
- **Final completion:** 2025-02
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348576, "Phase III Study to Evaluate the Efficacy and Safety of AD-209". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06348576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*